[Tirzepatide : overview of clinical studies SURPASS in type 2 diabetes and SURMOUNT in obesity].

Dec 19, 2024Revue medicale de Liege

An overview of tirzepatide studies for type 2 diabetes and obesity

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗

Abstract

Tirzepatide, administered as a once-weekly injection, demonstrated a greater reduction in HbA1c and body weight compared to placebo and other treatments in six studies of the SURPASS programme.

  • The effectiveness of tirzepatide was observed in a dose-dependent manner at 5, 10, and 15 mg.
  • In the SURMOUNT programme, tirzepatide resulted in unprecedented weight loss among individuals with obesity or overweight and associated complications.
  • Weight loss with tirzepatide was linked to improvements in comorbidities such as sleep apnea syndrome and cardiovascular risk factors.
  • Two large cardiovascular outcome trials are currently assessing tirzepatide's safety and efficacy in patients with type 2 diabetes and obesity.

AI simplified

Related papers

Aug '22
Tirzepatide’s effects on blood sugar control in type 2 diabetes
cited by 1 paper
randomized controlled trial
Jan '23
New developments in medicines targeting two gut hormones for treating type 2 diabetes
top 30% journal
cited by 55 papers
journal article
Feb '24
Simulated blood sugar and weight loss changes when switching weekly diabetes medication from semaglutide or dulaglutide to tirzepatide
top 30% journal
cited by 6 papers
journal article
Sep '22
Tirzepatide, a medicine targeting two hormone receptors, may better control blood sugar and reduce weight in type 2 diabetes
top 2% journal
cited by 296 papers
research support, non-u.s. gov't
Feb '24
Tirzepatide and its use in type 2 diabetes
top 2% journal
cited by 41 papers
journal article
Nov '21
Tirzepatide, a new medicine that activates two blood sugar hormones, as a potential heart and metabolism treatment
top 2% journal
cited by 97 papers
journal article
Dec '24
Tirzepatide for managing overweight and obesity
top 30% journal
cited by 20 papers
journal article
Dec '22
Reaching blood sugar goals with weight loss and no low blood sugar using the once-weekly drug tirzepatide in type 2 diabetes
cited by 33 papers
randomized controlled trial
Feb '24
Tirzepatide as a new heart-protecting treatment for type 2 diabetes and obesity
cited by 21 papers
journal article
Feb '23
Effectiveness and Safety of Tirzepatide for Managing Type 2 Diabetes and Obesity
top 5% journal
cited by 101 papers
journal article

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
2 days ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
1 week ago7 studies
issue #33
Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes
2 weeks ago7 studies
issue #32
60% of weight lost on GLP-1 drugs returns within a year of stopping
3 weeks ago7 studies
issue #31
Semaglutide linked to 54% lower risk of new sleep apnea cases in 1.25 million patients
4 weeks ago7 studies
issue #30
Tirzepatide beats semaglutide for heart protection in 70,672 non-diabetic adults with obesity
5 weeks ago7 studies
issue #29
Stopping GLP-1 drugs before endoscopy cuts stomach content risk from 25% to 3%
6 weeks ago7 studies
issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
7 weeks ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
8 weeks ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief